Come and join us across the globe
 Founded by Pr. Jacques Moret 
Sign In

Beyond the braid: Clinical evidence from a multi center early experience with the Surpass Elite® Flow Diverter

Last update on June 26, 2026

Emanuele Orru and Naga Kandasamy discussed the latest insights from the Elite Real study, a comprehensive, multi-center global registry evaluating Stryker's new-generation Surpass Elite® Flow Diverter. From complex intracranial aneurysms to daily practice variations, they analyzed early clinical data gathered across diverse global sites. Looking ahead, these preliminary results highlight how structural engineering advancements are driving greater predictability, streamlined sizing, and an improved safety profile in neurovascular interventions. 

Supported by Stryker

Structural advancements and streamlined sizing

The transition to the new-generation Surpass Elite® Flow Diverter introduces significant structural engineering changes that directly alter implant behavior. Unlike surface modifications, the increased braid angle of the device natively minimizes foreshortening.
Emanuele Orru emphasized a crucial paradigm shift for early adopters: the device is engineered to fit the largest vessel segment, as it is designed not to expand significantly beyond its nominal value. Sizing to the largest segment removes clinical guesswork and simplifies the deployment workflow. This predictability correlates with excellent conformability and wall apposition when navigating tight vascular bends, significantly reducing the need for advanced rescue maneuvers to correct non-opening segments or ribboning.

Real-world data, practice variations, and safety signals

The Elite Real study features a highly heterogeneous patient cohort across international sites (including California, Korea, and Ireland), capturing real-world clinical variations:

  • Angioplasty frequency: While institutional practices vary, the registry recorded a 20–22% angioplasty rate. Experts note routine post-dilation is low risk and microscopically enhances wall apposition.
  • Adjunct coiling: Coil usage sat at 10% in the global registry (often reserved for large or giant aneurysms) compared to over 90% in specific UK practices, showcasing distinct therapeutic strategies.

Despite these practice variations, aggregate early data showed an adequate occlusion rate approaching 90%. On the safety front, the results are overwhelmingly positive, demonstrating a very low percentage of in-stent stenosis and no device-related complications. As the core lab finishes independent adjudication, upcoming subgroup analyses will investigate performance across small versus giant aneurysms, alongside a separate data set dedicated to ruptured aneurysms.

On the same subject
Come and join us across the globe
 Founded by Pr. Jacques Moret